901494
N-Methylated pomalidomide
≥98%
别名:
4-Amino-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione, E3 Ligase ligand methylated negative control, Ligand for PROTAC® research
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C14H13N3O4
化学文摘社编号:
分子量:
287.27
MDL number:
UNSPSC Code:
12352101
NACRES:
NA.22
Assay:
≥98%
Form:
powder or crystals
ligand
N-Methylated Pomalidomide
Quality Level
assay
≥98%
form
powder or crystals
reaction suitability
reagent type: ligand
shipped in
wet ice
storage temp.
2-8°C
SMILES string
O=C(C(CC1)N(C2=O)C(C3=C2C=CC=C3N)=O)N(C)C1=O
InChI
1S/C14H13N3O4/c1-16-10(18)6-5-9(13(16)20)17-12(19)7-3-2-4-8(15)11(7)14(17)21/h2-4,9H,5-6,15H2,1H3
InChI key
YSWQOCGODHPKED-UHFFFAOYSA-N
Application
N-Methylated pomalidomide is a ligand used as a negative control for pomalidomide (P0018) in the recruitment of the Cereblon (CRBN) protein for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology.
Other Notes
Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation
Portal: Building PROTAC® Degraders for Targeted Protein Degradation
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Targeted Protein Degradation by Small Molecules
Small-Molecule PROTACS: New Approaches to Protein Degradation
Portal: Building PROTAC® Degraders for Targeted Protein Degradation
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Targeted Protein Degradation by Small Molecules
Small-Molecule PROTACS: New Approaches to Protein Degradation
Legal Information
PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
商品
Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.
Jing Lu et al.
Chemistry & biology, 22(6), 755-763 (2015-06-09)
BRD4, a bromodomain and extraterminal domain (BET) family member, is an attractive target in multiple pathological settings, particularly cancer. While BRD4 inhibitors have shown some promise in MYC-driven malignancies such as Burkitt's lymphoma (BL), we show that BRD4 inhibitors lead to
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Daniel P Bondeson et al.
Annual review of pharmacology and toxicology, 57, 107-123 (2016-10-13)
Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 901494-10MG-KC | 04065272218047 |
| 901494-25MG | 04061834671558 |